

Changes to the Michigan Pharmaceutical Product List (MPPL) and the Preferred Drug List (PDL) effective July 2008

The following changes will be made to the MPPL and to the PDL:

- Somatuline:** will be added to the Michigan Pharmaceutical Product List (MPPL)
- Azor:** will be added to the MPPL and to the Preferred Drug List (PDL) class “Antihypertensive Combinations: ARB-CCB” without prior authorization (PA)
- Flector patch;** will be added to the MPPL with PA
- Iquix:** will be added to the MPPL and to the PDL class “Ophthalmic Fluoroquinolones” with PA
- Veregen:** will be added to the MPPL with PA
- Combigan:** will be added to the MPPL and to the PDL as a class for “Combination Alpha 2 Adrenergic-Beta Blocker” in the Ophthalmics Section without PA
- Arcalyst:** will be added to the MPPL with PA
- Bystolic:** will be added to the MPPL and to the PDL class “Beta Blockers” without PA
- Renvela:** will be added to the MPPL and to the PDL class “Electrolyte Depleters” without PA
- Simcor:** will be added to the MPPL and to the PDL class “Lipotropics: Statins” with an electronic edit that will allow processing at point of service for any beneficiary who has a history of being on any statin and/ or niacin product; for other beneficiaries, PA will be required
- Adoxa CK kit:** will be added to the MPPL with PA
- Atralin gel:** will be added to the MPPL with the same parameters as the other tretinoin

Growth Hormones will be added as a new drug class with a diamond for clinical PA required to the PDL in the Miscellaneous Category; all products will be listed in bold

Ulcerative Colitis drugs (oral) will be added as a new class in the Gastrointestinal Category
Asacol, Pentasa, Sulfasalazine will be available without PA
Azulfidine DR, Balsalazide, Colazal, Dipentum and Lialda will require PA

A new PDL class, “Oxalodinones” listing Zyvox as available without PA will be added to the Antibiotics-Anti-Infectives.

Grifulvin V and Gris Peg will be added in addition to griseofulvin in the Antifungals-onychomycosis class

Cefprozil suspension will be added to the Cephalosporins 2nd Generation without PA and Cefzil suspension will require PA

Peg-Intron will be available without PA in the Hepatitis C class of the PDL

Ofloxacin otic will be added to the Otic Quinolones without PA and Floxin otic will require PA

Cetirizine will be available without PA in the “Anti-histamines 2nd Generation” class, and fexofenadine will require PA